Joint Reconstruction Devices Market is expected to reach US$ 39.87 Billion by 2031

Knee Segment to Lead Joint Reconstruction Devices Market Growth Based on Type During 2025–2031

According to our new research study on “Joint Reconstruction Devices Market Forecast to 2031 – Global Analysis – by Type, Technique, and End User,” the joint reconstruction devices market size is expected to grow from US$ 28.06 billion in 2024 to US$ 39.87 billion by 2031; the market is expected to register a CAGR of 5.3% during 2025–2031. Major factors driving the joint reconstruction devices market growth include the rising aging population, advancements in biomaterials and surgical technologies, and escalating prevalence of lifestyle-induced musculoskeletal disorders.

Joint reconstruction devices are medical implants and associated surgical instruments designed to restore function, reduce pain, and replace or repair damaged joints caused by arthritis, trauma, or degenerative conditions. The surge in 3D printing and additive manufacturing for patient-specific implants, expansion of AI and robotic-assisted systems for precision surgery, rise of regenerative biomaterials and biodegradable implants are expected to be major joint reconstruction devices market trends in the coming years.

Joint Reconstruction Devices Market, by Region, 2024 (%)

Source: The Insight Partners Analysis

Joint Reconstruction Devices Market Analysis Based on Segmental Evaluation:

Based on type, the joint reconstruction devices market is segmented into knee, hip, shoulder, ankle, and others. In 2024, the knee segment held a significant joint reconstruction devices market share. The market for knee joint reconstruction, mostly the total knee arthroplasty (TKA), has expanded significantly over the last few years due to the influence of the aging demographic and implant technology improvements. In 2024, the American Joint Replacement Registry (AJRR) documented the milestone of 4.3 million hip and knee arthroplasties, which indicates a significant increase in the number of procedures being tracked. By March 2024, this registry had gone beyond 4 million recorded procedures, which is a clear indication of a steady increase in the demand for knee reconstructions to relieve severe osteoarthritis and post-traumatic arthritis. Taking cemented knee arthroplasty constructs as an example, patients aged 65 and above show revision rates of 2% to 3% at 10 years, owing to which this technique has been durable and widely adopted. The forecasts show that the annual number of TKA surgeries could be 2.9 million by 2060, which is a 659% increase from the 2019 volume. This increase is due to the enhanced recovery protocols that have led to the reduction of the length of stay (LOS) trend. Moreover, posterior-stabilized implants like the Zimmer Biomet Persona that incorporate patient-specific instrumentation for better alignment and lowered incidents such as infections, which are reported in less than 1% of cases among patients, have benefited from this trend. These innovations make knee reconstruction the foundation of future orthopedic care, which, on the one hand, balances technological breakthrough with, on the other hand, long-term therapy to help billions of people regain their lost mobility.

The scope of the joint reconstruction devices market report includes an assessment of the market performance in North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa. In terms of revenue, North America dominated the joint reconstruction devices market share in 2024.

The arthroplasty devices market in the US is significantly influenced by a very high number of arthritis-related conditions that affect millions of people and thus create a demand for reconstructive interventions. As per the CDC, in 2022, about 18.9% of adults, which is more than 53 million individuals, have been diagnosed with arthritis, out of which osteoarthritis (OA) is the most prevalent form, affecting 32.5 million adults, mainly the elderly of 65 years and above. Moreover, rheumatoid arthritis (RA), an autoimmune disorder, affects approximately 1.5 million people in the country. Such disorders are characterized by chronic joint pain, stiffness, and degeneration, leading to surgical reconstruction in most cases. As an example, total knee arthroplasty (TKA) is a procedure in which the damaged areas of the knee are removed and replaced with prosthetic pieces made of metal alloys, polyethylene, and ceramics to revive the function of the joint; on the other hand, total hip arthroplasty (THA) consists of the usage of modular stems, acetabular cups, and femoral heads to both stabilize and relieve pain in a hip joint weakened by OA or fractured. According to the American College of Rheumatology, the number of total knee replacement surgeries in the US is approximately 790,000 per year, and THA is conducted around 544,000 times yearly. Furthermore, forecasts show an increase to 1.28 million knee replacements and 635,000 hip replacements by 2030, which represent 189% and 171% growth, respectively, as a result of the rising disease burden.

At the core of this sector's development lies the concept of continuous innovation, as shown by their recent actions. Zimmer Biomet got the FDA Breakthrough Device Designation for the world's first iodine-treated total hip replacement system, basically in October 2025. The facility is designed to provide infection risk reduction by releasing antimicrobial agents and to enhance osseointegration simultaneously. In about 20 years of intensified research, several key areas of the TKA were notably improved; most importantly, the concept of using robot-assisted surgery tools has been rapidly adopted in many surgical intervention units. This approach boosts surgeon precision when implanting, thus the post-op complications lessen by about 20%. In parallel with this, new biomaterials such as oxidized zirconium for wear-resistant surfaces are being introduced, as well as patient-specific 3D-printed implants are coming in handily prepared via preoperative imaging. These developments have been made possible along with the use of augmented reality navigation systems. The implant longevity has been extended up to 20–25 years, and the recovery period has been shortened as well. The combination of demographic and lifestyle factors has driven the expansion of joint reconstruction. The aging population is a factor that is increasing the number of cases of OA because the process of cartilage degradation is intensifying after age 50. The cancer treatment areas have been improved greatly by advancements in technology that have given rise to the development of minimally invasive methods, biologics usage, and stem cell-covered implants of the body. Consequently, the outcomes have been magnified and the procedures have become more accessible. The promotion of early intervention by public health initiatives and the extension of insurance coverage are two of the measures that remove barriers and thus enable a sustained demand. All these components make the US a player at the forefront of joint reconstruction, where the intersection of disease epidemiology and state-of-the-art engineering has brought about a complete transformation of how mobility is experienced by the increasingly arthritis-ridden population.

Stryker Corp, Smith & Nephew Plc, Medtronic Plc, Globus Medical Inc, Conmed Corp, B Braun SE, Zimmer Biomet Holdings Inc, Johnson & Johnson, Enovis Corp, and MicroPort Scientific Corp. are among the leading companies profiled in the joint reconstruction devices market report.

Based on type, the joint reconstruction devices market is segmented into knee, hip, shoulder, ankle, and others. By technique, the market is segmented into joint replacement, resurfacing, osteotomy, and others. In terms of end user, hospitals, orthopedic clinics, ambulatory surgical centers, and others. In terms of geography, the market is categorized into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of APAC), South and Central America (Brazil, Argentina, and the Rest of SAM), and the Middle East and Africa (Saudi Arabia, the UAE, South Africa, and the Rest of Middle East and Africa).

Contact Us

Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com